- Home
- Making Gains in HFpEF: An Appraisal of Where We Are Now
Making Gains in HFpEF: An Appraisal of Where We Are Now
- Heart Failure
Available Credit:
- Not accredited
Course Published On:
Course Expiry Date:
Overview
In this symposium, we focus on the management of HFpEF and hear from an esteemed faculty on the totality of evidence that places SGLT-2 inhibitors as the only drug class to significantly improve mortality and morbidity in patients with a left ventricular ejection fraction >40%. In addition to hearing about the data which led to changes in the recent ACC guidelines, we’ll also explore the impact of clinical inertia and the remaining challenges in HFpEF management.
This symposium is part of Heart Failure Online 2022, a world-class virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes.
Support Statement
This symposium is supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance. The scientific programme has not been influenced in any way by the sponsors.
It is not intended for US or UK based healthcare professionals.
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
Learning Objectives
Upon participation in this programme physicians will be able to:
- Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
- Recall current inertia rates amongst prescribers who manage heart failure
- Adopt effective treatment strategies for HFpEF patients early in the disease course
- Recall current guideline directed medical therapy options in HFpEF
- Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| Presentation & Discussion | Patient Case: Typical Patient with HFpEF | 15 mins | Shelley Zieroth (Manitoba, CA) |
| Presentation & Discussion | SGLT-2 Inhibitors in HFpEF: Totality of Evidence in a Nutshell | 15 mins | Javed Butler (Texas, US) |
| Presentation & Discussion | Early Initiation of Foundational Therapy in HF: Why The Urgency? | 15 mins | Carolyn Lam (Singapore, SG) |
SGLT-2 Inhibitors in HFpEF: Totality of Evidence in a Nutshell
Duration: 15 mins
Speakers: Javed Butler (Texas, US)
Early Initiation of Foundational Therapy in HF: Why The Urgency?
Duration: 15 mins
Speakers: Carolyn Lam (Singapore, SG)
Related Courses
- 1.00
Published:
Learning objectives
- Define residual inflammatory risk (RIR) and explain why cardiovascular events continue to occur in patients despite optimal lipid-lowering and antihypertensive therapies
- Describe the pathophysiological role of inflammation in atherosclerosis, myocardial infarction, heart failure and chronic kidney disease
- Identify patients at increased cardiovascular risk due to elevated inflammatory markers, particularly high-sensitivity C-reactive protein (hsCRP)
- Interpret the clinical significance of hsCRP and other inflammatory biomarkers in primary and secondary prevention settings, in alignment with current evidence and guideline recommendations
- Assess clinician practices, barriers and strategies for integrating inflammatory risk assessment and management
- Apply key takeaways to inform future risk assessment and treatment decisions in patients with or at risk for cardiovascular disease
- 1.00
Published:
Learning objectives
- Summarise the long-term burden and current unmet needs for patients with HF and EF ≥40%
- Recall data on new therapies being evaluated in the HFmr/pEF population, including data from the AHA 2024 annual congress
- Describe how non-steroidal MRAs differ in their mechanism of action and elicit their benefits in HF
- 1.00
Published:
Learning objectives
- Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
- Select appropriate patients for advanced medical therapy
- Recall recent trial data for novel therapeutic approaches
- Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF
- 1.25
Published:
Learning objectives
- To identify high-risk patient features indicative of worsening Heart Failure (HF)
- Name validated tools for serial prognostic assessment and risk stratification
- Adopt the use of appropriate assessment tools during patient follow-up
- Recall rates of recurrent HF events and their associated healthcare costs in worsening HF patients
- Recall the clinical benefit of emerging treatments targeted to treating worsening HF
- Initiate available treatment for the tailored management of worsening HF
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
- 0.50
Published:
Learning objectives
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice
- Not accredited
Published:
Learning objectives
- Recall guideline recommendations for the use of NT-proBNP in heart failure
- Describe current practices in heart failure diagnosis and the impact on treatment outcomes
- Develop an optimised approach to the timely diagnosis and management of heart failure
- 2.00
Published:
Learning objectives
- Recall clinical evidence and guidelines for the management of CKD patients without diabetes
- Describe current gaps and barriers in evidence-based management for CKD without diabetes
- Apply evidence based-management strategies to a case study
- Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes